AURKA and neoplasm: For patients with high AURKA-CN tumours, the median PFS on first-line chemotherapy was 11.5 months vs 7.7 months for patients with low AURKA-CN tumours (HR=0.56, 95% CI: 0.28–1.1, P=0.094; Figure 3A).